Appendix cancer medical therapy: Difference between revisions
(Created page with "__NOTOC__ {{Appendix cancer}} {{CMG}}; {{AE}} ==Overview== There is no treatment for [disease name]; the mainstay of therapy is supportive care. OR Supportive therapy for [...") |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[:File:///C:/jb-UTD/contents/mobipreview.htm?40/0/40967?source=see link|capecitabine]] or 5-FU with or without a platinum drug | |||
FOLFOX regimen (5- [[:File:///C:/jb-UTD/contents/mobipreview.htm?32/32/33280?source=see link|fluorouracil]] , [[:File:///C:/jb-UTD/contents/mobipreview.htm?23/54/24423?source=see link|leucovorin]] , and [[:File:///C:/jb-UTD/contents/mobipreview.htm?2/11/2233?source=see link|oxaliplatin]]) | |||
There is no treatment for [disease name]; the mainstay of therapy is supportive care. | There is no treatment for [disease name]; the mainstay of therapy is supportive care. | ||
Line 53: | Line 57: | ||
===Disease Name=== | ===Disease Name=== | ||
* | * | ||
* | |||
*** | **** '''Modified FOLFOX6''' : Cycle length 14 days | ||
**** | ***** [[drug name|'''Oxaliplatin''']] 85 mg/m <sup>2</sup> IV | ||
***** Dilute with 250 mL 5 percent dextrose in water (D5W) | |||
**** | ***** Administer over 2 hrs | ||
* | ***** ''Avoid extravasation: May cause significant tissue damage'' | ||
**** | ***** '''Leucovorin''' 400 mg/m <sup>2</sup> IV (d,l-racemic mixture) / 200 mg/m <sup>2</sup> IV (l-leucovorin) | ||
** | ***** Dilute with 250 mL D5W | ||
*** | ***** Administer over 2 hrs concurrent with oxaliplatin. | ||
**** | ***** [[drug name|'''Fluorouracil (FU)''']] 400 mg/m <sup>2</sup> IV bolus | ||
***** Slow IV push over 5 mins (administer immediately after leucovorin) | |||
***** [[drug name|'''Fluorouracil (FU)''']] 2400 mg/m <sup>2</sup> IV | |||
***** | ***** Administer immediately after FU IV bolus | ||
***** | ***** Dilute with 500 to 1000 mL D5W | ||
***** | ***** Administer over 46 hours | ||
**** | *** '''Doses should be recalculated if there is a 10 percent or more change in body weight.''' | ||
***** | *** | ||
***** | *** In order to decrease chance of developing Oxaliplatin induced neuropathy recommend patients to avoid exposure to cold up to 48 hours after each infusion. | ||
***** | *** '''Prior to each treatment''' | ||
***** | *** Assess changes in neurologic function | ||
** | *** Assess electrolytes and liver and renal function | ||
*** | *** CBC with differential and platelet count | ||
**** | ** '''Diarrhea:''' | ||
*** | ** Grade 2 or worse diarrhea, | ||
**** | ** Withhold treatment | ||
** Restart at a lower dose of FU after complete resolution | |||
** '''Severe diarrhea, mucositis, and myelosuppression after FU''' <math>\blacktriangledown</math> | |||
** Evaluate for dihydropyrimidine dehydrogenase deficiency | |||
*** | |||
** | |||
** | |||
==References== | ==References== |
Revision as of 22:36, 29 January 2019
Appendix cancer Microchapters |
Diagnosis |
---|
Treatment |
Appendix cancer medical therapy On the Web |
American Roentgen Ray Society Images of Appendix cancer medical therapy |
Risk calculators and risk factors for Appendix cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
capecitabine or 5-FU with or without a platinum drug
FOLFOX regimen (5- fluorouracil , leucovorin , and oxaliplatin)
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
- Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
- Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Disease Name
- Modified FOLFOX6 : Cycle length 14 days
- Oxaliplatin 85 mg/m 2 IV
- Dilute with 250 mL 5 percent dextrose in water (D5W)
- Administer over 2 hrs
- Avoid extravasation: May cause significant tissue damage
- Leucovorin 400 mg/m 2 IV (d,l-racemic mixture) / 200 mg/m 2 IV (l-leucovorin)
- Dilute with 250 mL D5W
- Administer over 2 hrs concurrent with oxaliplatin.
- Fluorouracil (FU) 400 mg/m 2 IV bolus
- Slow IV push over 5 mins (administer immediately after leucovorin)
- Fluorouracil (FU) 2400 mg/m 2 IV
- Administer immediately after FU IV bolus
- Dilute with 500 to 1000 mL D5W
- Administer over 46 hours
- Modified FOLFOX6 : Cycle length 14 days
- Doses should be recalculated if there is a 10 percent or more change in body weight.
- In order to decrease chance of developing Oxaliplatin induced neuropathy recommend patients to avoid exposure to cold up to 48 hours after each infusion.
- Prior to each treatment
- Assess changes in neurologic function
- Assess electrolytes and liver and renal function
- CBC with differential and platelet count
- Diarrhea:
- Grade 2 or worse diarrhea,
- Withhold treatment
- Restart at a lower dose of FU after complete resolution
- Severe diarrhea, mucositis, and myelosuppression after FU <math>\blacktriangledown</math>
- Evaluate for dihydropyrimidine dehydrogenase deficiency